Achievement of <scp>HbA1c</scp> and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in <scp>UK</scp> primary care: A retrospective, real‐world study
Two thirds of T2D patients receiving QW injectable GLP-1 RA for 6 months did not attain target HbA1c < 7%, and less than half and one-quarter of patients achieved ≥5% and ≥10% weight loss, respectively. Results suggest an unmet need for better clinical management of T2D in UK primary care.
Authors
- Monica Seif (ORCID: https://orcid.org/0000-0002-6130-1996)
- Katrien Wijndaele (ORCID: https://orcid.org/0000-0003-2199-7981)
- Lill‐Brith von Arx (ORCID: https://orcid.org/0000-0002-7170-6268)
- Robert Wood (ORCID: https://orcid.org/0000-0002-6977-435X)
- Joanne Webb (ORCID: https://orcid.org/0000-0001-6996-9897)
- Kamlesh K. Khunti (ORCID: https://orcid.org/0000-0003-2343-7099)
- R Wild (ORCID: https://orcid.org/0000-0002-9963-6441)
- Kunal Gulati
- Thomas Jennison (ORCID: https://orcid.org/0000-0001-7455-4442)
- Antonia Geneidat
Institutions
- University of Leicester (GB)
- Leicester General Hospital (GB)
- Herlev Hospital (DK)
- Adelphi Group (United Kingdom) (GB)
- Eli Lilly (United Kingdom) (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1111/dom.16201
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- National Institute for Health and Care Research
- Novo Nordisk
- Servier
- NIHR Leicester Biomedical Research Centre